Epogen Biosimilar Jury Verdict May Ignite New 'Safe Harbor' Battle
Executive Summary
Amgen awarded $70m in damages after jury finds certain batches of Hospira's Epogen biosimilar infringed a manufacturing process patent; case offers 'juicy legal issue' for Federal Circuit to address.
You may also be interested in...
Pfizer’s EPO Biosimilar Stalls In US On Hospira Compliance Woes
US FDA hands Pfizer its second complete response letter for its proposed biosimilar to Epogen/Procrit, citing manufacturing compliance concerns at a legacy Hospira manufacturing facility in Kansas that was the target of a February warning letter. Issue “is not directly related to EPO itself,” Pfizer’s Salomon Azoulay says.
Biosimilar Litigation: Genentech Avastin Suit Tossed; Janssen Remicade Case Uncertain
US court dismisses Genentech suit over Amgen's patent dance moves; Janssen v. Celltrion trial is postponed as parties fight over Janssen's standing to sue; and Amgen wants to bar AbbVie citizen petition filers from seeing its Amjevita information.
GDUFA Collections Fell Short In FY 2021
The US FDA reports that GDUFA met all of its 11 performance enhancement goals in FY 2021, while BsUFA is on track to meet 16 of 27 of its performance enhancement goals.